Sign Up for a Free Account
  • Updated 12.18.2021
  • Released 02.14.1994
  • Expires For CME 12.18.2024

Primary CNS lymphoma

Introduction

Overview

Primary central nervous system lymphoma is an extranodal non-Hodgkin lymphoma that arises within and is confined to the nervous system, including the brain, spinal cord, leptomeninges, and eyes. In this article, the author discusses developments in the management of primary central nervous system lymphoma.

Key points

• Primary central nervous system lymphoma is a non-Hodgkin (typically B-cell) lymphoma that arises within, and generally remains confined to, the nervous system.

• Staging work-up differentiates primary CNS lymphoma from extra-CNS lymphoma with CNS involvement.

• In the immunocompromised setting, the disease is often associated with the Epstein-Barr virus.

• Treatment options include systemic chemotherapy, intra-CSF chemotherapy, radiotherapy, and targeted therapies. High-dose methotrexate forms the backbone of many treatment protocols.

Historical note and terminology

Primary central nervous system lymphoma was first described in 1929 by Bailey (06). Over the following 2 to 3 decades, cerebral lymphoma was recognized as a discrete entity but described under a variety of names including reticulum cell sarcoma, histiocytic sarcoma, and microglioma, highlighting the debate regarding the malignant cell of origin; however, modern immunohistochemical studies definitively established the lymphocytic nature of this tumor.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125